Organization
Evelo Biosciences
8 clinical trials
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque PsoriasisStatus: Completed, Estimated PCD: 2021-07-02
Clinical trial
A Phase 1, Single Centre, Open Label, Crossover Study in Healthy Volunteers Using Scintigraphy to Evaluate the Gastrointestinal Behaviour of EDP1815 Oral Dosage Forms.Status: Completed, Estimated PCD: 2022-08-11
Clinical trial
A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsStatus: Completed, Estimated PCD: 2021-06-30
Clinical trial
A Phase 2 Double-blind Placebo-controlled Study Investigating the Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With SARS-CoV-2 InfectionStatus: Terminated, Estimated PCD: 2021-05-16
Clinical trial
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Cohort Study Investigating the Effect of EDP1815 in Participants for the Treatment of Mild, Moderate and Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2023-03-09
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Dose Platform Study Investigating the Immunopharmacology of EDP1815 and EDP2939.Status: Completed, Estimated PCD: 2022-10-14
Clinical trial
A Ph1a/1b, First in Human, Participant and Investigator-blind Sponsor-unblinded Randomized Placebo-controlled Multiple Dose Study of EDP1867 in Healthy Volunteers & Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild AsthmaStatus: Completed, Estimated PCD: 2022-02-28
Clinical trial
A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous Phase 2 And 3 EDP1815 TrialsStatus: Terminated, Estimated PCD: 2023-05-25